In obese individuals, GLP-1 infusion acutely decreased creatinine clearance (29); however, in other infusion studies with the GLP-1 receptor agonist exenatide, measured GFR (mGFR) was increased in healthy volunteers (26) and unchanged in people with T2D (30). Here, GLP1R is linked to type 2 diabetes mellitus.